

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>HOLISTA COLLTECH LIMITED</b>
<b>ABN</b>	<b>094 515 992</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Rajendran Marnickavasagar
<b>Date of last notice</b>	8 February 2019

#### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	-
<b>Date of change</b>	3 April 2020
<b>No. of securities held prior to change</b>	<b>Direct</b> 20,921,027 Ordinary Fully Paid Shares 3,600,000 Class A Performance Rights 2,700,000 Class B Performance Rights 1,800,000 Class C Performance Rights 900,000 Class D Performance Rights  <b>Indirect</b> 58,514,245 Held by Galen Biomedical Inc. (director controlled entity)
<b>Class</b>	Ordinary Fully Paid Shares
<b>Number acquired</b>	6,300,000
<b>Number disposed</b>	-
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<b>Direct</b> 27,221,027 Ordinary Fully Paid Shares  1,800,000 Class C Performance Rights 900,000 Class D Performance Rights  <b>Indirect</b> 58,514,245 Held by Galen Biomedical Inc. (director controlled entity)
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Conversion of 3,600,000 Class A Performance Rights and 2,700,000 Class B Performance Rights (Refer to ASX Announcement dated 8 April 2020 titled 'Achievement of Performance Rights Milestones')

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	-
<b>Nature of interest</b>	-
<b>Name of registered holder (if issued securities)</b>	-
<b>Date of change</b>	-
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	-
<b>Interest acquired</b>	-
<b>Interest disposed</b>	-
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	-
<b>Interest after change</b>	-

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.  
 01/01/2011